FLT3 and acute myeloid leukemia: The mutational spectrum in ALL differs from that in AML, with reports of non-canonical variants involving tyrosine kinase domain hotspots (e.g., D835) and the juxtamembrane (JXM) domain, both capable of driving constitutive FLT3 activation [29,30].